Antibody-drug conjugates (ADCs) are rapidly transforming the therapeutic landscape of metastatic breast cancer (MBC), reshaping treatment selection and sequencing across multiple disease subtypes. Agents targeting HER2 and TROP2 have demonstrated clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) across HER2-positive, HER2-low/ultralow, and triple-negative breast cancer populations. Recent pivotal trials, along with updated NCCN guideline recommendations, are expanding the role of ADCs into earlier lines of therapy and in combination with immunotherapy. As a result, clinicians must increasingly navigate complex decisions regarding patient selection, optimal sequencing of multiple ADCs, management of unique toxicity profiles, and integration of emerging ADC-based strategies with established endocrine, targeted, and HER2-directed therapies. In this program, expert-led presentations will contextualize emerging clinical trial data and guideline updates. At the same time, interactive case discussions will allow faculty to explore real-world decision-making challenges related to ADC selection, sequencing, toxicity management, and treatment personalization in MBC. This educational activity is an archive of the live virtual symposium held during the 25th Annual International Congress on the Future of Breast Cancer(R) East on July 10, 2026.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 259 Prospect Plains Rd, Bldg H
Pricing
100% of listed courses are free
265 of 265 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Infectious Disease
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Neurosurgery
- Nuclear Medicine
- Ophthalmology
- Pediatric Hematology-Oncology
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Surgical Oncology
- Urological Oncology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Board review / self-assessment
- includes Virtual patient / simulation
- Credit · Up to 1.5 credits
- Commercial Support
-
ReleasedJul 31, 2026
-
Last day to claim creditAug 1, 2027 10 months left
-
Medscape, LLC Implementing Clinical Metagenomic Sequencing Tests for Immunocompromised Populations
-
Global Learning Collaborative Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
-
Clinical Care Options, LLC (dba Decera Clinical Education) Global Perspectives on Sequencing Therapy in Relapsed/Refractory CLL
-
Physicians’ Education Resource Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer
-
Physicians’ Education Resource Show Me Your Care Plan!(TM) Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management
-
Physicians’ Education Resource Advancing Targeted Therapy in HR+/HER2- Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice
